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Abstract
Background: Mycoplasma fermentans has been associated with rheumatoid arthritis. Recently, it
was detected in the joints and blood of patients with rheumatoid arthritis, but it is not clear yet
how the bacteria enter the body and reach the joints. The purpose of this study was to determine
the ability of M. fermentans to induce experimental arthritis in rabbits following inoculation of the
bacteria in the trachea and knee joints.
Methods: P-140 and PG-18 strains were each injected in the knee joints of 14 rabbits in order to
evaluate and compare their arthritogenicity. P-140 was also injected in the trachea of 14 rabbits in
order to test the ability of the bacteria to reach the joints and induce arthritis.
Results: M. fermentans produced an acute arthritis in rabbits. Joint swelling appeared first in rabbits
injected with P-140, which caused a more severe arthritis than PG-18. Both strains were able to
migrate to the uninoculated knee joints and they were detected viable in the joints all along the
duration of the experiment. Changes in the synovial tissue were more severe by the end of the
experiment and characterized by the infiltration of neutrophils and substitution of adipose tissue
by connective tissue. Rabbits intracheally injected with P-140 showed induced arthritis and the
bacteria could be isolated from lungs, blood, heart, kidney, spleen, brain and joints.
Conclusion: M. fermentans induced arthritis regardless of the inoculation route. These findings
may help explain why mycoplasmas are commonly isolated from the joints of rheumatic patients.
Background
Numerous studies have demonstrated that some viruses
and bacteria including mycoplasmas could be related
with the pathogenesis of arthritis [1–4]. The primary hab-
itats of human and animal mycoplasmas are the mucous
surface of the respiratory and urogenital tracts, the eyes,
mammary glands and joints [5]. Mycoplasmas have been
incriminated as causative agents of arthritis since they
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were found in rats and mice with natural arthritis 50 years
ago [6,7]. Bartholomew isolated M. hominis, M. hyorhinis
and M. arthritidis from the synovial fluid in 14 of 17 pa-
tients with rheumatoid arthritis, systemic lupus erythema-
tosus and Reiter's Syndrome in 1965 [8].
Williams et al. reported the presence of Mycoplasma fer-
mentans in the synovial fluid of patients with rheumatoid
arthritis [7], but these results could not be reproduced in
further investigations probably because of the fastidious
growth requirements of the microorganism [9]. Recently,
in 1997, Schaeverbeke et al. using molecular biology tools
detected and also isolated M. fermentans in joints of pa-
tients with rheumatoid arthritis and other joint disorders
[10,11]. Further, Johnson et al. detected M. fermentans by
PCR in 88% of synovial fluid samples from patients with
different arthritis [2].
Schaeverbeke et al. studied and compared the genotypic
characteristics of seven strains isolated from the synovial
fluid of patients with arthritis with three reference strains
of the bacteria [12]. Recent studies have also shown the
presence of M. fermentans DNA and specific antibodies to
the bacteria in the synovial fluid of patients with rheuma-
toid arthritis [13]. This mycoplasma has been detected in
blood of patients with rheumatoid arthritis, producing
systemic mycoplasmal infections [14], these results sug-
gest that M. fermentans may play a role in the development
of the disease. Some mycoplasmas may act as unspecific
mitogens of B and T cells, while other mycoplasma (M. ar-
thritidis) produce MAM, which shows superantigenic ac-
tivity [5,15]. M. fermentans possesses a potent
immunomodulator product named macrophage activat-
ing lipopeptide 2 (MALP-2) which activates macrophages
to release cytokines which may in turn increase the neu-
trophilic infiltrate into the joint. MALP-2 could induce the
release of macrophage-derived 5'-nucleotidase, this en-
zyme may occur in joints in excessive amounts when M.
fermentans is present in patients with rheumatoid arthritis
[16]. These abilities are used by mycoplasmas during the
induction of natural arthritis in animals.
Mycoplasmas are common inhabitants of the human res-
piratory and genitourinary tracts where they produce
chronic infections, they also are able to invade other tis-
sues and in some cases induce an autoimmune response
[5]. Pathogenesis of some human mycoplasmal infections
is poorly understood, that is the case of Mycoplasma fer-
mentans. Even this microorganism has been isolated in the
joints of rheumatic patients; it is not clear how the bacte-
ria enter the body and how they reach the joints. On the
basis of these observations we attempted to experimental-
ly reproduce an arthritic disease in rabbits employing a M.
fermentans strain isolated from the respiratory tract of hu-
mans. The second purpose of this study was to test if this
strain when injected in the respiratory tract was able to
reach the joints and induce arthritis.
Methods
Bacterial strains and growth conditions
M. fermentans P-140 was isolated from the respiratory tract
of asthmatic patient in our laboratory [17] and M. fermen-
tans PG-18 was a kind gift of Dr. Gail H. Cassell (Univer-
sity of Alabama at Birmingham).
The strains were grown at 37°C in l liter of E broth consist-
ing of 2.1% (wt/vol.) PPLO broth base (Difco), 20%
(vol./vol.) horse serum, 0.002% (wt/vol.) phenol red,
0.25% (wt/vol.) glucose and 10% (vol./vol.) yeast extract.
Animal model
Forty-nine New Zealand-White rabbits weighing 3 to 4 kg
were used. The animal protocol complied with all relevant
and institutional policies including the Helsinki Declara-
tion. Blood and throat swabs of animals were checked for
the genus mycoplasma by culture and PCR in order to de-
termine that rabbits were mycoplasma free.
Arthritogenic ability of M. fermentans
The right knee joints of 14 rabbits were injected with 0.1
ml of a broth culture that contained 1 ×  106 colony form-
ing units per milliliter (CFU/ml) of Mycoplasma fermentans
P-140. Also 14 rabbits were injected with 0.1 ml of broth
cultures that contained 1 ×  106 CFU/ml of Mycoplasma fer-
mentans PG-18. The left joint received no treatment and
was considered a control. As negative controls seven rab-
bits were injected with 0.1 ml of E broth (mycoplasma
free) in the right knee joint.
An increase in the joint diameter was considered an indi-
cator of joint swelling. The diameters were measured twice
every third day during the experiment. Two rabbits of each
experimental group and one from the control group were
sacrificed on day 3,5,8,13,20,27 and 34 after the injection.
Both the left and right synovia received the same treat-
ment; the synovial membrane was divided in two parts.
The presence of viable mycoplasmas was determined by
inoculating one half of the synovial membrane in l ml of
E broth and ten fold serial dilutions were also cultured an
inoculated onto agar [18]. Blood cultures were performed.
The presence of aerobic flora in synovium was determined
by plating sheep blood agar plates. Knee synovia were re-
moved and immediately fixed in 10% formalin pH 7.0.
Samples were embedded in paraffin, sectioned and
stained with hematoxilin and eosin.
Arthritis induced by M. fermentans after tracheal injection
Fourteen New Zealand white rabbits were intracheally in-
jected with 0.1 ml of a broth culture that contained 1 ×
106 CFU/ml of Mycoplasma fermentans P-140. Valuation ofBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/15
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joint swelling and sacrifice of the animals were performed
in the same way as in the experiment about M. fermentans
arthritogenic ability. Five milliliters of blood were extract-
ed from heart and cultured before sacrifice. Animals were
sacrificed by the injection of 5 ml of Anesthesal. Brain, tra-
chea, lungs, heart, spleen, kidney and knee joints were ex-
tracted, 1 cm3 of tissue or half of the synovia were
deposited in 0.9 ml of E broth and ten fold serial dilutions
were also done [18]. Tissue and synovial cultures, and his-
topathological study of the synovia were performed as de-
scribed in the experiment of arthritogenic ability of M.
fermentans.
DNA amplification
A Polymerase Chain Reaction (PCR) test was used to con-
firm the presence of M. fermentans in synovial tissues. The
oligonucleotide primers used for PCR detection were
RW004 5'(GGACTATTGTCTAAACAATTTCCC) 3' and
RW005 5'(GGTTATTCGATTTCTAAATCGCCT) 3' de-
signed by Wang, which amplified a 206-nucleotide specif-
ic gene sequence within the insertion sequence-like
element that exist in multiple copies only in the M. fer-
mentans genome [19]. Before we used this PCR based test
to detect M. fermentans, we confirmed the specificity of
these primers.
The reaction mixture contained 50 mM KCl, 1.5 mM
MgCl2, 10 mM Tris-HCL (pH 8.3), 0.2 mM of each deox-
ynucleotide triphosphate, 6 µM of each primer and 1 unit
of AmpliTaq® (Perkin Elmer Cetus, Emerville, CA.) in a to-
tal volume of 50 µl. The sample to be analyzed (5 µl) was
always added last. A diluted lysate of M. fermentans PG-18
corresponding to 100 CCU and sterile water were used as
positive and negative controls respectively. The amplifica-
tion involved 40 cycles, each consisted of denaturation at
95°C for 25 s, primers annealing at 60°C for 60 s and ex-
tension at 72°C for 60 s. The amplified products were an-
alyzed by electrophoresis in 2% agarose gels and
visualized by UV light after ethidium bromide staining.
Statistics
Many researchers use at least three animals for each time
point for a better statistical and experimental reproduc-
tion. Although, animal models offer several advantages,
one disadvantage is the cost. We used 49 rabbits in our
study and it represented a considerable cost so we were
not able to use a greater amount of animals. In previous
studies where we used the rabbit model to test the arthri-
togenic ability of M. pneumoniae, M. pulmonis and M. ar-
thritidis[22] we injected 6 animals with each strain and we
had a small standard deviations and small animal-animal
variations. These facts gave us the confidence to use only
2 rabbits in each time point. However, the use of only two
animals may lower the statistical power of the results. The
Mann Whitney U-statistic was used to assess the statistical
difference between articular diameters of M. fermentans
PG-18 and P-140 and to compare the recovery of myco-
plasmas in the knee synovial samples. The Kruskall-Wallis
test was used to compare M. fermentans PG-18, P-140 in-
traarticular injected, P-140 intracheally injected and con-
trol.
Results
When animal models are used it is important to check that
they are mycoplasma free because the presence of these
microorganisms would change the results. The rabbits
that we used were free of any genus of mycoplasma in the
sites tested.
Arthritogenic ability of M. fermentans
One goal of this study was to experimentally reproduce ar-
thritis in rabbits employing a clinical isolate from the hu-
man respiratory tract and compare it with the arthritis
produced by a type strain. We used a strain isolated from
the respiratory tract instead of one from joints because we
wanted to test that a mycoplasma isolated from the hu-
man respiratory tract was able to induce arthritis. We
found that rabbits inoculated with Mycoplasma fermentans
P-140 showed increases of five percent in the knee joint
diameter during the first seven days postinoculation. Then
a decreased was observed, during the days 11 and 15, joint
diameters increased to 3.5% and other increase (4 %) in
volume of the joint was observed on days 17 and 19. (Ta-
ble 1).
Joint increments induced by Mycoplasma fermentans PG-18
were lesser than those induced by M. fermentans P-140.
The only significant increment of the joint diameter
(3.8%) produced by M. fermentans PG-18 was observed
on day 23. This increase was similar in magnitude to the
second increase induced by M. fermentans P-140 (Table 1).
After 27 days a slow decrease of the joint diameter was ob-
served in both groups of rabbits.
The group of rabbits that received E broth showed a min-
imum increment of the joint diameter (0.7%), starting in
the day three and on day 15 the inflammation disap-
peared. Kruskall-Wallis test showed statistical differences
(P < 0.0001) in the increases of the joint diameter induced
by experimental group respect to control group. No statis-
tical difference was observed in joint diameters between
M. fermentans PG-18 and P-140. M. fermentans P-140 in-
duced more severe inflammation in right knee joints than
PG-18 (p < 0.005).
Detection and quantitation of Mycoplasmas
Synovial samples obtained from knee joints injected with
M. fermentans P-140 and PG18 showed 197 and 95 CFU/
ml of the organisms respectively, after three days postin-
oculation (p < 0.05). At the end of the experiments theBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/15
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number of mycoplasmas isolated dropped to 37 and 29
respectively (p > 0.05). In the left knee joints (which were
not inoculated) 38 CFU/ml of P-140 were recovered dur-
ing the first three days and 25 CFU/ml of PG-18, by the
end of the experiment 43 CFU/ml and 35 CFU/ml, respec-
tively were recovered. A significant difference (P = 0.01)
was observed in the recovery of M. fermentans PG-18, be-
tween right and left synovium (Table 2). Aerobic bacteria
were not isolated from the culture in blood agar. Both
strains were recovered from blood cultures, suggesting
that mycoplasmas reach the blood stream and this could
explain in part why the uninoculated knee joints con-
tained mycoplasmas by the end of the experiment. PCR
detection showed 206-bp products in the synovium sam-
ples. Control rabbits did not show amplified fragments.
Arthritis induced by M. fermentans after intracheal injec-
tion
Once we observed that M. fermentans P-140 was able to in-
duce arthritis when it was intraarticular injected, our goal
was to test if M. fermentans P-140 was able to induce ar-
Table 1: Increases of joint diameter in rabbits injected with M. fermentans P-140, PG-18 and controls.
Days I.A. P-140*
(S.D.) I.A. PG-18*
(S.D.) Controls*
(S.D.) Animals**
I.T. P-140 (S.D.)
1 0 (0.0) 0 (0) 0 (0) 14 0 (0.0)
3 4.6 (0.9) 0.3 (0.8) 0.5 (0.2) 12 0.3 (0.2)
5 5.5 (0.6) 0.6 (0.9) 0.7 (0.3) 10 1.3 (0.4)
7 5.3 (0.8) 1.6 (0.5) 0.6 (0.2) 10 1.6 (0.7)
9 4.4 (0.7) 1.8 (0.8) 0.5 (0.4) 8 2.6 (0.2)
11 2.1 (0.6) 1.7 (0.6) 0.6 (0.1) 8 2.7 (0.1)
13 2.9 (0.5) 1.7 (0.4) 0.3 (0.2) 6 3.0 (0.3)
15 3.5 (0.7) 1.7 (0.8) 0 (0.0) 6 2.6 (0.1)
17 4.0 (0.5) 2.8 (0.6) 0 (0.0) 6 1.9 (0.1)
19 4.3 (0.3) 3.6 (0.4) 0 (0.0) 6 1.8 (0.1)
21 3.8 (0.1) 3.5 (0.2) 0 (0.0) 4 0.8 (0.2)
23 3.3 (0.4) 3.8 (0.2) 0 (0.0) 4 0.4 (0.0)
25 2.9 (0.3) 3.3 (0.4) 0 (0.0) 4 0 (0.0)
27 2.5 (0.2) 3.1 (0.2) 0 (0.0) 2 0 (0.0)
29 2.5 (0.3) 2.4 (0.1) 0 (0.0) 2 0 (0.0)
31 2.5 (0.2) 2.4 (0.4) 0 (0.0) 2 0 (0.0)
33 2.5 (0.5) 2.4 (0.2) 0 (0.0) 2 0 (0.0)
* The values are reported as percentages of increases in joint diameter. ** The means reported come from these numbers of animals. (The diame-
ters were measured twice every third day during the experiment. Two rabbits of each experimental group and one from the control group were 
sacrificed on day 3,5,8,13,20,27 and 34 after the injection.) I.A. = Intraarticular injected I.T. = Intracheally injected S.D. = Standard deviation
Table 2: Recovery of Mycoplasma fermentans from the synovial membrane of rabbits.
P-140 Right Synovium PG-18 Right Synovium P-140 Left Synovium PG-18 Left Synovium
Days* CFU S.D. CFU S.D. CFU S.D. CFU S.D.
3 197 (4.2) 95 (7.07) 38 (2.8) 25 (4.24)
5 169 (5.65) 88 (5.65) 47 (5.65) 32 (4.24)
8 142 (5.65) 80 (5.65) 45 (2.8) 41 (4.24)
13 84 (7.07) 52 (7.07) 41 (2.8) 38 (7.07)
20 57 (2.8) 43 (5.65) 36 (7.07) 32 (5.65)
27 42 (2.8) 52 (7.07) 40 (7.07) 28 (4.24)
34 37 (2.8) 29 (4.2) 43 (5.65) 35 (5.65)
• Days after the intraarticular injection of mycoplasmas • Each value of CFU is the mean of two animals. Abbreviations: CFU = colony forming units. 
S.D. = standard deviation.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/15
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thritis when it was injected in the respiratory tract of rab-
bits.
After M. fermentans injection in the trachea, the microor-
ganism was detected by culture and PCR in blood, brain,
lungs, heart, spleen, kidney and both knee joints suggest-
ing that M. fermentans reached the joints by blood. Three
days after tracheal inoculation M. fermentans induced a
small increase in joint diameter, the greatest increase was
observed on day 13, then joint diameters reached the orig-
inal size (diameter before M. fermentans injection) (table
1). Unfortunately we did not quantify mycoplasmas in
the knee joints but we detected the bacteria by culture and
PCR in both joints.
Histological findings
Histological examination of the control group revealed a
layer of adipose tissue surrounded with a slim synovial
membrane. (Figure 1). M. fermentans P-140 generates his-
tological dramatic changes with respect to PG-18, 27 and
34 days postinjection. Mainly histological changes were
characterized by the infiltration of neutrophils, synovial
membrane proliferation and inflammation. The substitu-
tion of adipose tissue by connective tissue and the pres-
ence of plasmatic cells were more marked toward the day
30. M. fermentans P-140 showed greater amounts of neu-
trophils and a complete substitution of adipose tissue by
connective tissue. (Figure 2). While, in M. fermentans PG-
18 there was not a complete substitution of adipose tissue
by connective tissue.
Discussion
Mycoplasmas are common causes of natural arthritis in
animals. Mycoplasmas may infect the respiratory and gen-
itourinary tracts, mammary glands and joints of animals
and humans [20]. It has been difficult to determine the
etiological agents of rheumatoid arthritis in humans due
to its multifactorial nature, but animal models have
proved to be helpful in these regards. Animal models have
been useful to determine the role of mycoplasmas as ar-
thritogenic agents but the outcome of these experimental
models depends on several factors such as the inmmuno-
logical state of the host, the virulence of the microorgan-
ism inoculation site, size and concentration of the
inoculum [21]. Washburn et al. showed that rabbit is a
good model to test the arthritogenic ability of M. pulmonis
and M. arthritidis[18]. In a previous study we used the rab-
bit model to show that M. pneumoniae was able to induce
arthritis [22]. This arthritogenic ability is important be-
cause M. pneumoniae may produce extra-respiratory com-
plications in human beings [22]. The pathogenic role of
M. fermentans has not been completely defined. The aim
of this study was to test and compare the arthritogenic
ability of a clinical isolate of the respiratory tract with a
type strain and to test if M. fermentans P-140 when inject-
ed in the trachea is able to reach the joints and induce ar-
thritis. M. fermentans P-140 injected in the joints induced
a more severe arthritis than the one induced by M. fermen-
tans PG-18 strain during the first days postinoculation
showing a greater ability to migrate to the uninoculated
left knee joint than PG-18 strain. The histological study of
synovial tissue revealed few changes in the knee joints in-
jected with PG-18. However, when rabbits were injected
with the P-140 strain a marked local inflammatory re-
sponse with fibroblast and cellular infiltration, constitut-
ed by lymphocytes and plasma cells were shown. M.
fermentans P-140 has been isolated from the human respi-
ratory tract [17], it has had few passages in the laboratory
Figure 1
Histological examination (40X) of knee synovium from nega-
tive control group, showing 2–3 layers of synovial cells that
surround adipose tissue.
Figure 2
Histological findings (40X) of knee synovium from M. fermen-
tans P-140 infected group, showing hyperplasia of synovial
cells (more than 10 layers). A complete replacement of adi-
pose cells by connective tissue in the presence of inflamma-
tory cells is also observed.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/15
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while PG-18 is a type strain isolated from the genitouri-
nary tract and has been passed in the laboratory several
times, so the lower arthritogenic ability of M. fermentans
PG-18 could be attributed to the fact that mycoplasmas
show attenuation of virulence by continuous broth pas-
sage [21,23,24].
Mycoplasma fermentans persisted in the joints during all
the experiment but fewer colony forming units were re-
covered from knee joints of rabbits by the end of the
study. The fact that P-140 was recovered from synovia sug-
gests that this anatomical site or environment is a suitable
biological niche for the bacteria. Several other studies
have shown that the destruction of epithelial cells during
arthritis; promotes the growth of mycoplasmas by the re-
lease of substances, which can be used as nutrients by
mycoplasmas, and it creates the basis for further damage
to the joint [25]. Washburn et al. and Kirchhoff et al.
showed that microbial products or the mere cellular le-
sion could stimulate the secretion of cytokines, which
play an important role in the development of arthritis
[18,25].
Since the joint seems to be a natural habitat for Mycoplas-
ma fermentans it is reasonable to assume that the organ-
isms are at least partially protected from the host defense
mechanisms and are able to survive for several days after
injection. We isolated viable M. fermentans P-140 and PG-
18 five weeks after injection in both joints. The isolation
of mycoplasmas from blood suggests that M. fermentans
could have used this route to reach the left knee joint. The
transient arthritis that we observed in the right knees also
suggests mycoplasma persistence after injection.
Once we tested the arthritogenic ability of M. fermentans it
was important to determine if the microorganism was
able to reach the joints and induce arthritis when it was in-
jected in the trachea. The respiratory tract could be one of
the natural entrances of M. fermentans to human body.
Two days after the inoculation of M. fermentans to the tra-
chea the bacteria have already reached the blood, joints,
lungs, spleen, brain, kidney and heart of rabbits. In the
joints it was able to induce an inflammatory response that
began on day three after injection, the most severe inflam-
mation was observed on day 13 then the inflammatory re-
sponse decreased, on day 25 the rabbits have already
reached their initial joint diameter. Some differences were
observed between animals injected in the trachea and the
ones injected in the knee joints. When animals were in-
traarticular injected, the microorganism induced a more
severe inflammatory response than the one induced by M.
fermentans injected in the trachea. Probably because the
bacteria did not have to evade the defense mechanism of
the host, the microorganisms are deposited directly in the
joints where they reproduce, liberate toxic substances,
produce tissue damage and induce arthritis. When M. fer-
mentans is injected in the trachea, the bacteria have to
evade the host defense responses of the respiratory tract,
pass to the blood and later reach the joints where they re-
produce and induce arthritis. When M. fermentans were in-
jected in the trachea they induced a less severe arthritis
that disappeared in few days, the histopathological dam-
age was also resolved and the animals recovered the initial
joint diameters.
Although M. fermentans is a human pathogen suspected to
be involved in the induction of arthritis since 1970 [7], its
pathogenesis mechanisms are poorly understood. It is not
known how M. fermentans reaches the joints and induces
arthritis. The detection of M. fermentans in joints of rheu-
matic patients incriminates this microorganism as a cause
of arthritis in humans [10,11]. In a previous study, we iso-
lated these bacteria from the respiratory tract in 6 % of a
population of asthmatic patients [17]. So it is probable
that the primary site of infection of M. fermentans may be
the respiratory tract, which serves as a niche for dissemi-
nation or translocation of the mycoplasmas to the joints
via blood stream and induce arthritis.
What are the bacterial determinants responsible for induc-
ing arthritis remains to be elucidated. We found here that
a clinical M. fermentans isolate obtained from the respira-
tory tract of a patient with asthma [17] was able to induce
arthritis in a rabbit model and when injected in the tra-
chea the microorganism reached the joints and induced
arthritis. We believe our observations will shed light on
new avenues to study the bacterial molecules responsible
of the arthritogenic potential of M. fermentans.
Conclusions
This study shows that a strain of M. fermentans isolated
from the human respiratory tract has the ability to induce
arthritis in an animal model. Based on the reported data
available and the present observations it is tempting to
speculate that primary respiratory tract infections may
lead to the migration of mycoplasmas to joints and to the
development of arthritis.
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